OmniScreen™ is a high throughput screening service for multiple oncology drug compounds in a single-go (lead compounds) across a diverse set of cancer cell-lines. It is your best shot to assess the early efficacy and potency of your oncology drug candidates by running initial screens with large-scale cancer cell line panels saving you cost and time.
This technology groups cell lines together based on specific characteristics suitable to the study. It offers diverse quality-controlled screening panels for you to screen your drug compounds in targeted manner. These panels include-
OmniPanel™ – It is a growing collection of >520 cancer cell lines for drug response screening providing complete analysis of the drug compound in vitro.
XenoSelect™ – This panel consists of >210 cancer cell lines and respective xenograft models to rapidly proceed to in vivo pharmacology studies.
RNAseq Panel which includes >240 cancer cell-lines with in-house genomic data such as mutation status, copy number variation and expression levels because of drug response.
PrimePanel™ – It comprises a growing collection of >30 unique primary cancer cell lines derived from PDX (patient-derived tumour tissues for in vitro screening). The ease to link this in vitro data to in vivo and further to clinical efficacy is a speciality of this subpanel enabling discovery of some predictive biomarkers.
XenoBase® is a database with curation of >1000 cancer-lines, can be used to build a custom panel and enhance your usability.
You can take control of your experiment with OmniScreen™ and get unrivaled flexibility to design the screening panels you need. The study can further be customised with flexible template designs by adjusting or extending incubation times and obtaining multiple sets of data from the test samples.
Crown Bioscience, the company behind this technology, ensures that screening results between cancer cell types are consistent by keeping a strict check on:
• Cell line quality – Annotated, well-characterized, SNP/STR verified, mycoplasma tested
• Differences between cell culture media
• Variations in incubation times and treatment responses
• Seeding densities across multiple time points
• Chemotherapeutic agents, and vehicle controls
The personalized support from their bioinformatics team for novel targets and biomarkers help you with obtaining:
• Dose-response curve graphs
• Combination index graphs
• Inhibition heat maps for concentration combinations
• 2D contour maps
• 3D response surface plots
• Guided analysis and reporting
In addition to the unique features offered by this technology, you can also monitor the incoming data real-time via secure online client accounts.
This screening runs every 3 months and internal drug controls and cell line revival costs are covered by Crown Bioscience ensuring a substantial amount of cost cutting.
To increase the efficiency of the outcome, OmniScreen™ keeps historical data from over 100 studies. You can make informed predictions on cell line growth parameters and responses to specific drug candidates based on how specific cell lines previously responded to drug candidates. This gives you an opportunity to maintain clear relevance to in vivo models and real-life clinical settings.
OmniScreen™ is an excellent solution to assess the early efficacy and potency of oncology drug candidates by running initial screens with large-scale cancer cell line panels, saving both time and costs. With its unique features, customized panels, and personalized support, it is the best shot for clients to achieve their desired results.
*GVRP is the authorized distributor of Crown Bioscience services in India. Contact us for more information on how to get started with OmniScreen™ for your projects.
Sai Supriya has a 2 year experience in academic research and fair exposure to transition into industry. She enjoys delving deep into the new developments in the biotech, pharma industry and collaborating with people. She is zealous and keen to direct her best strengths to the role by being receptive to new ideas and challenges.